Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Forecast & Price Target
Zenas BioPharma, Inc. Common Stock · NASDAQ
$32.34-0.48 (-1.46%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Zenas BioPharma, Inc. Common Stock, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $22.00 to $55.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $40.50 sits 25% above the current $32.34. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.31 next quarter toward $-2.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Zenas BioPharma, Inc. Common Stock.
As of Jul, 5 of 6 firms rate ZBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-1.31
Range $-1.46 – $-1.16 · 2 analysts · +7% YoY
Next period, 2 analysts expect Zenas BioPharma, Inc. Common Stock to earn $-1.31 a share (range $-1.46 – $-1.16), versus $-1.22 a year earlier. Full-year consensus is $-4.29, growing to $-2.27 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $36.3M, rising to $63.7M next year.
Top analysts covering Zenas BioPharma, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZBIO.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$55.00+70.1% to target
Overall win rate
52%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$44.00+36.1% to target
Overall win rate
56%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$41.00+26.8% to target
Overall win rate
43%
+ Follow
#4
Judah Frommer
Morgan Stanley
Hold
$22.00-32.0% to target
Coverage
—
+ Follow
#5
Cory Kasimov
Evercore ISI Group
Buy
$55.00+70.1% to target
Coverage
—
+ Follow
ZBIO stock forecast FAQ
What is ZBIO's average 12-month price target?+
The 4 analysts with a live target average $40.50 for Zenas BioPharma, Inc. Common Stock over the next 12 months, ranging from a $55.00 high to a $22.00 low.
Is ZBIO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZBIO?+
The Street-high target is $55.00 (Guggenheim), and the Street-low is $22.00 (Morgan Stanley). The average of all 4 active targets is $40.50.
How many Wall Street analysts cover ZBIO?+
6 analysts have an active rating on Zenas BioPharma, Inc. Common Stock, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZBIO?+
Among analysts who currently cover ZBIO, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $55.00 target.
What is Zenas BioPharma, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.31 per share (range $-1.46 – $-1.16) across 2 analysts. Full-year EPS is projected at $-4.29, rising to $-2.27 the following year.
How much revenue is Zenas BioPharma, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $36.3M, growing to $63.7M next year.
Have analysts been upgrading or downgrading ZBIO lately?+
As of Jul, 5 of 6 firms rate ZBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
